However, RIPOR2 was expressed at significantly higher levels in normal tissues than tumor tissues in patients with bladder urothelial carcinoma, breast invasive carcinoma, CC, colon adenocarcinoma (COAD), glioblastoma (GBM), kidney chromophobe, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma, prostate adenocarcinoma, rectum adenocarcinoma (READ), and uterine corpus endometrial carcinoma (UCEC). Here, RIPOR2 is linked to invasive breast carcinoma.